Results 111 to 120 of about 36,718 (285)
ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Therapeutics and Clinical Risk Management, 2017 David Feder,1 Miriam Eva Koch,1 Beniamino Palmieri,2 Fernando Luiz Affonso Fonseca,1 Alzira Alves de Siqueira Carvalho3 1Pharmacology Department, Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil; 2Department of General Surgery ...
Feder D +4 more
doaj
Paradoxical Cerebral Fat Embolism in Revision Hip Surgery
Case Reports in Orthopedics, 2014 The incidence of clinical fat embolism syndrome (FES) is low (
Nicolás S. Piuzzi +4 more
doaj +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
Clinical Utility of Intra-Operative 6 Hydroxyethyl Starch (130 / 0.4) Supplementation in Hypoxemic Femur Injury Patients: A Preliminary Report of Twenty Cases [PDF]
, 2012 : Posttraumatic intravasation of fat and debris can lead to a cascade of events. Hydroxyethyl starches (HES) markedly suppress neutrophil influx by decreasing pulmonary capillary permeability and facilitating tissue oxygenation by improving ...
Das Puri, G. +3 more
core
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
A skin lesion after cardiac catheterization [PDF]
, 2012 Alaminos, Miguel +6 more
core +2 more sources
European Journal of Heart Failure, EarlyView.The diagnosis of atrial cardiomyopathy (AtCM) requires electrical atrial dysfunction, with evidence of either mechanical atrial dysfunction, atrial enlargement, or excessive atrial fibrosis. The diagnostic cut‐points presented are for standard electrocardiogram and echocardiogram studies (see Figure 1 for further detail).
Jerremy Weerts +26 more
wiley +1 more source
Deep phenotyping of heart failure with preserved ejection fraction through multi‐omics integration
European Journal of Heart Failure, EarlyView.Deep phenotyping of of heart failure with preserved ejection fraction (HFpEF) through multi‐omics integration. AI, artificial intelligence. Aims Heart failure with preserved ejection fraction (HFpEF) has become the predominant form of heart failure and a leading cause of global cardiovascular morbidity and mortality.
Jakob Versnjak +15 more
wiley +1 more source
European Journal of Heart Failure, EarlyView.Aims Major adverse cardiovascular events (MACE) related to cardiovascular disease are a major cause of death in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). We explored the impact of MASLD on incident MACE and overall mortality in the general population in Germany.
Yvonne Huber +15 more
wiley +1 more source